Study investigators cautioned against routine use of the device in complex percutaneous coronary interventions and to treat ...

Two separate randomized trials of Johnson & Johnson’s miniaturized Impella heart pumps failed to illustrate the devices’ ...

The results challenge the rapid growth of Impella support during high-risk PCI. Investigators say a reckoning is needed.

Randomized trials neutral for pump device in complex elective cases, STEMI with reperfusio ...

In the STEMI Door-to-Unload trial, use of Impella missed the mark in patients with anterior MI without cardiogenic shock.

A combination of left ventricular support plus delayed percutaneous coronary intervention did not reduce infarct size compared with immediate PCI in patients with anterior STEMI without shock, ...

Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't ...

Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't have cardiogenic shock does not significantly reduce heart damage.

Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't have cardiogenic shock ...

Full-year gross margins Enhanced Balance Sheet Flexibility with an Additional $2.5 million Proceeds from Amended Credit Facility in November Implemented Strategic Workforce and Cost Reduction Program ...

In 2025, we made significant strides towards advancing DrugSorb-ATR - a two-time U.S. Food and Drug Administration (FDA) Breakthrough Device - through the FDA De Novo submission process to reduce ...

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on ...